Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.
Jeffrey Seow,Carl Graham,Blair Merrick,Sam Acors,Suzanne Pickering,Kathryn J. A. Steel,Oliver Hemmings,Aoife M O'Byrne,Neophytos Kouphou,Rui Pedro Galão,Gilberto Betancor,Harry Wilson,Adrian W. Signell,Helena Winstone,Claire Kerridge,Isabella Huettner,Jose M. Jimenez-Guardeño,Maria Jose Lista,Nigel J. Temperton,Luke B Snell,Karen Bisnauthsing,Amelia E. B. Moore,Adrian Green,Lauren Martinez,Brielle Stokes,Johanna Honey,Alba Izquierdo-Barras,Gill Arbane,Amita Patel,Mark Kia Ik Tan,Lorcan O’Connell,Geraldine O’Hara,Eithne MacMahon,Sam Douthwaite,Gaia Nebbia,Rahul Batra,Rocio T. Martinez-Nunez,Manu Shankar-Hari,Manu Shankar-Hari,Jonathan D. Edgeworth,Jonathan D. Edgeworth,Stuart J. D. Neil,Michael H. Malim,Katie J. Doores +43 more
Reads0
Chats0
TLDR
The present study has important implications when considering widespread serological testing and antibody protection against reinfection with SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection.Abstract:
Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10-15 d after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-2 in the human population, it is not known how long antibody responses will be maintained or whether they will provide protection from reinfection. Using sequential serum samples collected up to 94 d post onset of symptoms (POS) from 65 individuals with real-time quantitative PCR-confirmed SARS-CoV-2 infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) in >95% of cases and neutralizing antibody responses when sampled beyond 8 d POS. We show that the kinetics of the neutralizing antibody response is typical of an acute viral infection, with declining neutralizing antibody titres observed after an initial peak, and that the magnitude of this peak is dependent on disease severity. Although some individuals with high peak infective dose (ID50 > 10,000) maintained neutralizing antibody titres >1,000 at >60 d POS, some with lower peak ID50 had neutralizing antibody titres approaching baseline within the follow-up period. A similar decline in neutralizing antibody titres was observed in a cohort of 31 seropositive healthcare workers. The present study has important implications when considering widespread serological testing and antibody protection against reinfection with SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection.read more
Citations
More filters
Journal ArticleDOI
Evolution of antibody immunity to SARS-CoV-2.
Christian Gaebler,Zijun Wang,Julio C. C. Lorenzi,Frauke Muecksch,Shlomo Finkin,Minami Tokuyama,Alice Cho,Mila Jankovic,Dennis Schaefer-Babajew,Thiago Y. Oliveira,Melissa Cipolla,Charlotte Viant,Christopher O. Barnes,Yaron Bram,Gaëlle Breton,Thomas Hagglof,Pilar Mendoza,Arlene Hurley,Martina Turroja,Kristie Gordon,Katrina G. Millard,Victor A. Ramos,Fabian Schmidt,Yiska Weisblum,Divya Jha,Michael Tankelevich,Gustavo Martinez-Delgado,Jim Yee,Roshni Patel,Juan Dizon,Cecille Unson-O'Brien,Irina Shimeliovich,Davide F. Robbiani,Zhen Zhao,Anna Gazumyan,Robert E. Schwartz,Theodora Hatziioannou,Pamela J. Bjorkman,Saurabh Mehandru,Paul D. Bieniasz,Paul D. Bieniasz,Marina Caskey,Michel C. Nussenzweig,Michel C. Nussenzweig +43 more
TL;DR: In this article, the authors report on the humoral memory response in a cohort of 87 individuals assessed at 1.3 and 6.2 months after infection with SARS-CoV-2.
Journal ArticleDOI
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.
Sheila F Lumley,Denise O'Donnell,Nicole Stoesser,Philippa C Matthews,Alison Howarth,Stephanie B Hatch,Brian D. Marsden,Stuart Cox,Tim James,Fiona Warren,Liam J Peck,Thomas G Ritter,Z de Toledo,Laura Warren,David Axten,Richard J. Cornall,E Y Jones,David I. Stuart,Gavin R. Screaton,Daniel Ebner,Sarah Hoosdally,Sarah Hoosdally,Meera Chand,D W Crook,D W Crook,O'Donnell A-M.,Christopher P. Conlon,Koen B. Pouwels,A S Walker,A S Walker,Peto Tea.,Susan Hopkins,Timothy M Walker,Katie Jeffery,David W Eyre +34 more
TL;DR: The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear as discussed by the authors.
Journal ArticleDOI
SARS-CoV-2 evolution during treatment of chronic infection.
Steven Kemp,Dami A. Collier,Dami A. Collier,Rawlings Datir,Isabella Ferreira,Salma Gayed,Aminu S Jahun,Myra Hosmillo,Chloe Rees-Spear,Petra Mlcochova,Ines Ushiro Lumb,David J. Roberts,Anita Chandra,Nigel J. Temperton,Katherine Sharrocks,Elizabeth Blane,Yorgo Modis,Yorgo Modis,Kendra E. Leigh,Kendra E. Leigh,John A. G. Briggs,Marit J. van Gils,Kenneth G. C. Smith,John Bradley,Chris Smith,Rainer Doffinger,Lourdes Ceron-Gutierrez,Gabriela Barcenas-Morales,David D. Pollock,Richard A. Goldstein,Anna Smielewska,Jordan P. Skittrall,Theodore Gouliouris,Ian Goodfellow,Effrossyni Gkrania-Klotsas,Christopher J. R. Illingworth,Laura E. McCoy,Ravindra K. Gupta +37 more
TL;DR: In this paper, the authors report chronic SARS-CoV-2 with reduced sensitivity to neutralizing antibodies in an immune suppressed individual treated with convalescent plasma, generating whole genome ultradeep sequences over 23 time points spanning 101 days.
Journal ArticleDOI
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
Joseph E. Ebinger,Justyna Fert-Bober,Ignat Printsev,Min Wu,Nancy Sun,John Prostko,Edwin C. Frias,James L. Stewart,Jennifer E. Van Eyk,Jonathan Braun,Susan Cheng,Kimia Sobhani +11 more
TL;DR: In this paper, the authors observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection were similar to those seen after two doses of vaccine in individuals without prior infection.
Journal ArticleDOI
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
Leticia Monin,Adam Laing,Miguel Muñoz-Ruiz,Duncan R. McKenzie,Irene del Molino del Barrio,Irene del Molino del Barrio,Thanussuyah Alaguthurai,Clara Domingo-Vila,Thomas Hayday,Carl Graham,Jeffrey Seow,Sultan Abdul-Jawad,Shraddha Kamdar,Elizabeth Harvey-Jones,Rosalind Graham,Jack Cooper,Muhammad Shamim Khan,Jennifer Vidler,Helen Kakkassery,Shubhankar Sinha,Richard Davis,Liane Dupont,Isaac Francos Quijorna,Charlotte O'Brien-Gore,Puay Ling Lee,Josephine Eum,Maria Conde Poole,Magdalene Joseph,Daniel Davies,Daniel Davies,Yin Wu,Angela Swampillai,Bernard V. North,Ana Montes,Mark Harries,Anne Rigg,James Spicer,James Spicer,Michael H. Malim,Paul Fields,Paul Fields,Piers E.M. Patten,Piers E.M. Patten,Francesca Di Rosa,Sophie Papa,Sophie Papa,Timothy Tree,Katie J. Doores,Adrian Hayday,Adrian Hayday,Sheeba Irshad,Sheeba Irshad +51 more
TL;DR: In this paper, the safety and immunogenicity of the BNT162b2 (Pfizer-BioNTech) vaccine in patients with cancer was evaluated using data from three London hospitals between Dec 8, 2020 and Feb 18, 2021.
References
More filters
Journal ArticleDOI
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Lisa A. Jackson,Evan J. Anderson,Nadine Rouphael,Paul C. Roberts,Mamodikoe Makhene,Rhea N. Coler,Michele Paine McCullough,James D. Chappell,Mark R. Denison,Laura J. Stevens,Andrea J. Pruijssers,Adrian B. McDermott,Britta Flach,Nicole A. Doria-Rose,Kizzmekia S. Corbett,Kaitlyn M. Morabito,Sijy O’Dell,Stephen D. Schmidt,Phillip A. Swanson,Marcelino Padilla,John R. Mascola,Kathleen M. Neuzil,Hamilton Bennett,Wellington Sun,Etza Peters,Mat Makowski,Jim Albert,Kaitlyn Cross,Wendy Buchanan,Rhonda Pikaart-Tautges,Julie E. Ledgerwood,Barney S. Graham,John H. Beigel +32 more
TL;DR: The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.
Journal ArticleDOI
Antibody responses to SARS-CoV-2 in patients with COVID-19.
Quanxin Long,Bai Zhong Liu,Hai Jun Deng,Gui Cheng Wu,Kun Deng,Yao Kai Chen,Pu Liao,Jing Fu Qiu,Yong Lin,Xue Fei Cai,Deqiang Wang,Yuan Hu,Ji Hua Ren,Ni Tang,Yin Yin Xu,Li Hua Yu,Zhan Mo,Fang Gong,Xiao-li Zhang,Wen Guang Tian,Li Hu,Xian Xiang Zhang,Jiang Lin Xiang,Hong Xin Du,Hua Wen Liu,Chun Hui Lang,Xiao He Luo,Shao Bo Wu,Xiao Ping Cui,Zheng Zhou,Man Man Zhu,Jing Wang,Cheng Jun Xue,Xiao Feng Li,Li Wang,Zhi Jie Li,Kun Wang,Chang Chun Niu,Qing Jun Yang,Xiaojun Tang,Yong Zhang,Xia Mao Liu,Jin Jing Li,De Chun Zhang,Fan Zhang,Liu Ping,Jun Yuan,Qin Li,Jie Li Hu,Juan Chen,Ailong Huang +50 more
TL;DR: It is suggested that SARS-CoV2-specific IgG or IgM seroconversion occurs within 20 days post symptom onset and may be helpful for the diagnosis of suspected patients with negative RT–PCR results and for the identification of asymptomatic infections.
Journal ArticleDOI
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.
Quanxin Long,Xiaojun Tang,Qiu Lin Shi,Qin Li,Hai Jun Deng,Jun Yuan,Jie Li Hu,Wei Xu,Yong Zhang,Fa Jin Lv,Kun Su,Fan Zhang,Jiang Gong,Bo Wu,Xia Mao Liu,Jin Jing Li,Jing Fu Qiu,Juan Chen,Ailong Huang +18 more
TL;DR: A cohort of asymptomatic patients infected with SARS-CoV-2 had significantly lower levels of virus-specific IgG antibodies compared to a cohort of age- and sex-matched symptomatic infected patients.
Journal ArticleDOI
Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
Davide F. Robbiani,Davide F. Robbiani,Christian Gaebler,Frauke Muecksch,Julio C. C. Lorenzi,Zijun Wang,Alice Cho,Marianna Agudelo,Christopher O. Barnes,Anna Gazumyan,Shlomo Finkin,Thomas Hagglof,Thiago Y. Oliveira,Charlotte Viant,Arlene Hurley,Hans Heinrich Hoffmann,Katrina G. Millard,Rhonda G. Kost,Melissa Cipolla,Kristie Gordon,Filippo Bianchini,Spencer T. Chen,Victor A. Ramos,Roshni Patel,Juan Dizon,Irina Shimeliovich,Pilar Mendoza,Harald Hartweger,Lilian Nogueira,Maggi Pack,Jill Horowitz,Fabian Schmidt,Yiska Weisblum,Eleftherios Michailidis,Alison W. Ashbrook,Eric Waltari,John E. Pak,Kathryn E. Huey-Tubman,Nicholas Koranda,Pauline R. Hoffman,Anthony P. West,Charles M. Rice,Theodora Hatziioannou,Pamela J. Bjorkman,Paul D. Bieniasz,Paul D. Bieniasz,Marina Caskey,Michel C. Nussenzweig,Michel C. Nussenzweig +48 more
TL;DR: Most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity, and rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
Journal ArticleDOI
A serological assay to detect SARS-CoV-2 seroconversion in humans.
Fatima Amanat,Daniel Stadlbauer,Shirin Strohmeier,Shirin Strohmeier,Thi H. O. Nguyen,Veronika Chromikova,Meagan McMahon,Kaijun Jiang,Guha Asthagiri Arunkumar,Denise Jurczyszak,Jose Polanco,Maria Bermudez-Gonzalez,Giulio Kleiner,Teresa Aydillo,Lisa Miorin,Daniel S. Fierer,Luz Amarilis Lugo,Erna Milunka Kojic,Jonathan Stoever,Sean T. H. Liu,Charlotte Cunningham-Rundles,Philip L. Felgner,Thomas M. Moran,Adolfo García-Sastre,Daniel Caplivski,Allen C. Cheng,Katherine Kedzierska,Olli Vapalahti,Jussi Hepojoki,Jussi Hepojoki,Viviana Simon,Florian Krammer +31 more
TL;DR: A serological enzyme-linked immunosorbent assay for the screening and identification of human SARS-CoV-2 seroconverters and can be adjusted to detect different antibody types in serum and plasma.
Related Papers (5)
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Jennifer M. Dan,Jennifer M. Dan,Jose Mateus,Yu Kato,Kathryn M. Hastie,Esther Dawen Yu,Caterina E. Faliti,Alba Grifoni,Sydney I. Ramirez,Sydney I. Ramirez,Sonya Haupt,April Frazier,Catherine Nakao,Vamseedhar Rayaprolu,Stephen A. Rawlings,Bjoern Peters,Bjoern Peters,Florian Krammer,Viviana Simon,Erica Ollmann Saphire,Erica Ollmann Saphire,Davey M. Smith,Daniela Weiskopf,Alessandro Sette,Alessandro Sette,Shane Crotty,Shane Crotty +26 more
Antibody responses to SARS-CoV-2 in patients with COVID-19.
Quanxin Long,Bai Zhong Liu,Hai Jun Deng,Gui Cheng Wu,Kun Deng,Yao Kai Chen,Pu Liao,Jing Fu Qiu,Yong Lin,Xue Fei Cai,Deqiang Wang,Yuan Hu,Ji Hua Ren,Ni Tang,Yin Yin Xu,Li Hua Yu,Zhan Mo,Fang Gong,Xiao-li Zhang,Wen Guang Tian,Li Hu,Xian Xiang Zhang,Jiang Lin Xiang,Hong Xin Du,Hua Wen Liu,Chun Hui Lang,Xiao He Luo,Shao Bo Wu,Xiao Ping Cui,Zheng Zhou,Man Man Zhu,Jing Wang,Cheng Jun Xue,Xiao Feng Li,Li Wang,Zhi Jie Li,Kun Wang,Chang Chun Niu,Qing Jun Yang,Xiaojun Tang,Yong Zhang,Xia Mao Liu,Jin Jing Li,De Chun Zhang,Fan Zhang,Liu Ping,Jun Yuan,Qin Li,Jie Li Hu,Juan Chen,Ailong Huang +50 more
Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
Davide F. Robbiani,Davide F. Robbiani,Christian Gaebler,Frauke Muecksch,Julio C. C. Lorenzi,Zijun Wang,Alice Cho,Marianna Agudelo,Christopher O. Barnes,Anna Gazumyan,Shlomo Finkin,Thomas Hagglof,Thiago Y. Oliveira,Charlotte Viant,Arlene Hurley,Hans Heinrich Hoffmann,Katrina G. Millard,Rhonda G. Kost,Melissa Cipolla,Kristie Gordon,Filippo Bianchini,Spencer T. Chen,Victor A. Ramos,Roshni Patel,Juan Dizon,Irina Shimeliovich,Pilar Mendoza,Harald Hartweger,Lilian Nogueira,Maggi Pack,Jill Horowitz,Fabian Schmidt,Yiska Weisblum,Eleftherios Michailidis,Alison W. Ashbrook,Eric Waltari,John E. Pak,Kathryn E. Huey-Tubman,Nicholas Koranda,Pauline R. Hoffman,Anthony P. West,Charles M. Rice,Theodora Hatziioannou,Pamela J. Bjorkman,Paul D. Bieniasz,Paul D. Bieniasz,Marina Caskey,Michel C. Nussenzweig,Michel C. Nussenzweig +48 more
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
Alba Grifoni,Daniela Weiskopf,Sydney I. Ramirez,Sydney I. Ramirez,Jose Mateus,Jennifer M. Dan,Jennifer M. Dan,Carolyn Rydyznski Moderbacher,Stephen A. Rawlings,Aaron Sutherland,Lakshmanane Premkumar,Ramesh Jadi,Daniel Marrama,Aravinda M. de Silva,April Frazier,Aaron F. Carlin,Jason A. Greenbaum,Bjoern Peters,Bjoern Peters,Florian Krammer,Davey M. Smith,Shane Crotty,Shane Crotty,Alessandro Sette,Alessandro Sette +24 more